Johnson & Johnson's knee sales up 94.6% in Q2; spine sales return to worldwide growth

Alan Condon -   Print  | Email

Johnson & Johnson's orthopedics second-quarter sales increased 53.4 percent to $2.2 billion year over year with the company's spine sales seeing a return to global growth.

Five notes:

1. Worldwide for the second quarter, hip sales increased 73.7 percent to $392 million, knee sales rose 94.6 percent to $350 million and trauma sales were up 24.8 percent to $710 million.

2. Second-quarter spine, sports and other segment sales increased 55.3 percent to $776 million.

3. Spine sales alone returned to worldwide growth, increasing 51.7 percent compared to the second quarter of 2020. Recently launched spine products include the company's Symfony device for complex cervical spine, the Conduit interbody platform for spinal fusion and the Fibergraft bone graft to promote fusion.

4. Johnson & Johnson's entire medical devices segment grew about 7 percent compared to the second quarter of 2019, with eight of its 11 "billion-dollar platforms showing growth versus 2019," Chris DelOrefice, vice president of investor relations, said during the company's July 21 earnings call, transcribed by Seeking Alpha.

5. The pace of recovery in the knee and spine segments has been slower than other markets as these procedures are perceived to be more deferrable by patients, Mr. DelOrefice said. 

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.